Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25331105
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 AAPS+J
2015 ; 17
(1
): 93-101
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Emerging technologies to increase ligand binding assay sensitivity
#MMPMID25331105
Fischer SK
; Joyce A
; Spengler M
; Yang TY
; Zhuang Y
; Fjording MS
; Mikulskis A
AAPS J
2015[Jan]; 17
(1
): 93-101
PMID25331105
show ga
Ligand binding assays (LBAs) have been the method of choice for protein analyte
measurements for more than four decades. Over the years, LBA methods have
improved in sensitivity and achieved larger dynamic ranges by using alternative
detection systems and new technologies. As a consequence, the landscape and
application of immunoassay platforms has changed dramatically. The introduction
of bead-based methods, coupled with single molecule detection standardization and
the ability to amplify assay signals, has improved the sensitivity of many
immunoassays, in some cases by several logs of magnitude. Three promising
immunoassay platforms are described in this article: Single Molecule Counting
(SMC?) from Singulex Inc, Single Molecule Arrays (Simoa?) from Quanterix
Corporation, and Immuno-PCR (Imperacer®) from Chimera Biotec GmbH. These
platforms have the potential to significantly improve immunoassay sensitivity and
thereby address the bioanalytical needs and challenges faced during
biopharmaceutical drug development.